Vaccine Info

Fluarix Quadrivalent Influenza Vaccine

Authored by
Last reviewed
September 27, 2022

Fluarix Quadrivalent Vaccine Description - 2022

Fluarix Quadrivalent is prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses is produced and purified separately. After harvesting the virus-containing fluids, each influenza virus is concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine is further purified by diafiltration.

Each influenza virus solution is inactivated by the consecutive effects of sodium deoxycholate and formaldehyde, leading to the production of a "split virus." Each split inactivated virus is then suspended. Fluarix Quadrivalent is thimerosal-free.

On September 26, 2022, the WHO has announced its vaccine composition for the 2023 southern hemisphere influenza season.  The U.S. FDA typically recommends the same composition for the US flu season.

Fluarix Quadrivalent for 2021 - 2022, quadrivalent (four-component) egg-based vaccines is recommended to contain: A/Victoria/2570/2019 (H1N1)pdm09-like virus, A/Cambodia/e0826360/2020 (H3N2)-like virus, B/Washington/02/2019 (B/Victoria lineage)-like virus, and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

CPT code: 90686; STN: BL 125127

Fluarix Quadrivalent Indication

Fluarix Quadrivalent is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Do not administer FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine.

A CDC Clinician Outreach and Communication Activity (COCA) call was held on September 15, 2022, to discuss recommendations for influenza prevention and treatment in Children.

Fluarix Quadrivalent Dosage

The preferred sites for intramuscular injection are the anterolateral thigh for children aged 6 through 11 months and the deltoid muscle of the upper arm for persons aged 12 months and older if muscle mass is adequate. 6 months through 8 years: Not previously vaccinated with influenza vaccine: Two doses (0.5-mL each) at least four weeks apart. Six months through 8 years: Vaccinated with influenza vaccine in a previous season: One or 2 doses (0.5-mL each) and 9 years and older: One 0.5-mL dose.

Fluarix Quadrivalent and COVID-19 Vaccines

The US Centers for Disease Control and Prevention (CDC) previously issued interim clinical considerations stating that 'COVID-19 vaccines and other vaccines, including influenza vaccines, can be administered without regard to timing. And the annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications. 'Providers should be aware of the potential for increased reactogenicity with coadministration and should consult the CDC for updated guidance as more information becomes available. If coadministered, COVID-19 vaccines and vaccines that might be more likely to cause a local reaction (e.g., aIIV4 or HD-IIV4) should be administered in different limbs, if possible.'

'No data are currently available concerning coadministration of currently Authorized COVID-19 vaccines and influenza vaccines,' stated Lisa Grohskopf, M.D., MPH, CDC's ACIP vaccine committee presentation (slide #14) on June 24, 2021.

Fluarix Quadrivalent Side Effects

Fluarix Quadrivalent is generally well-tolerated, however, if you or your loved one has an adverse reaction to the vaccine, that information should be reported to VAERS.

VAERS is a U.S. passive reporting system, meaning it relies on individuals to send in reports of their experiences to a vaccine. Anyone can submit a report to VAERS, including parents and patients. Furthermore, healthcare providers are required by law to report to VAERS.

Fluarix Quadrivalent News For 2020 - 2022

May 4, 2022 - The WHO reported for week 16 that globally, influenza activity remained low, but activity has increased since February 2022 after an initial decrease in January 2022. Detections were mainly influenza A(H3N2) viruses and B/Victoria lineage viruses.

April 8, 2022 - The CDC flu report FluView stated that influenza activity increased nationally this week.  The majority of flu viruses detected are A(H3N2).

February 9, 2022 - GSK reported Fluarix/FluLaval sales decreased in 2021 by 7% AER, 2% CER, to £679 million as a result of unfavorable prior period RAR movements in the US, partially offset by higher volume in the US and strong southern hemisphere demand in International.

November 11, 2021 - The WHO reported globally influenza detections remain low, but among the positive cases, influenza B viruses predominated.

October 16, 2021 - During week 41 the CDC reported 1.8% of patient visits reported through ILINet were due to ILI. Two jurisdictions experienced moderate activity while none reported high or very high.

October 7, 2021 - The UK weekly National influenza reported 8 influenza-positive case samples.

September 11, 2021 - The CDC reported that nationwide influenza-like illness continues to be below baselines.

September 4, 2021 - According to the US CDC influenza virus circulation remains low; therefore, increases in ILI activity are likely due to increased circulation of other respiratory viruses.

August 13, 2021 - Nationwide during week 31, 2.0% of patient visits reported through ILINet were due to ILI. Although increasing, the percentage of patient visits for ILI remains below the baseline of 2.6% nationally. One region (Region 7) is at its region-specific baseline while the remaining regions are below their baselines. Influenza virus circulation remains low; therefore, increases in ILI activity are likely due to increased circulation of other respiratory viruses.

July 28, 2021 - GSK announced its financial results. Fluarix/FluLaval sales grew by more than 100% AER and CER, to £33 million driven by strong southern hemisphere demand in International.

July 23, 2021 - GSK today announced it started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2021-22 flu season. "GSK's focus continues to be increasing vaccination rates during the COVID-19 pandemic and flu vaccination is an integral part of that public health effort," said Judy Stewart, Senior Vice President and Head of US Vaccines at GSK.

July 2, 2021 - The U.S. FDA confirmed 'We have approved your request submitted and received March 5, 2021, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act (42 U.S.C. 262) for Influenza Vaccine (Fluarix), manufactured at your Dresden, Germany facility, to include the 2021-2022 United States formulation and associated labeling revisions.'

July 28, 2020 - GSK expects to supply more than 50 million doses of its influenza vaccines for the US market in the 2020-21 season

Fluarix Quadrivalent Clinical Trials

Fluarix Quadrivalent Vaccine has been involved in over 220 clinical studies.